Search - tctmd.com

Displaying 161 - 180 of 543

Sort: Relevancy | Date

News Daily News

Low Rate of Bailout Emergency Surgery During TAVR, but Caution Still Needed

Michael O'Riordan

January 10, 2018

News Daily News

Sex Differences Diminish With Third-Generation TAVR Device

L.A. McKeown

January 05, 2018

Presentation

Sex-Specific Outcomes of TAVR With the SAPIEN 3 Valve

January 05, 2018

News Daily News

Novel Repositionable TAVR Device Sees Low Pacemaker Rates and Few Leaks

Shelley Wood

December 19, 2017

News Daily News

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

Caitlin E. Cox

November 30, 2017

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

Todd Neale

November 08, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

News Daily News

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Caitlin E. Cox

September 29, 2017

News Conference News PCR London Valves 2017

CT Scans Before and After TAVR Show Tricuspid, Bicuspid Valves Are Reassuringly Similar

Shelley Wood

September 28, 2017

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

Presentation

Association of PVR With 1-Year Outcomes After TAVR With Sapien 3 Valve

September 27, 2017

News Conference News ESC 2017

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

Michael O'Riordan

August 31, 2017

Manuscript

Standardized Minimalistic Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using the SAPIEN 3 Device: Stepwise Description, Feasibility, and Safety from a Large Consecutive Single-Center Single-Operator Cohort

August 08, 2017

News Daily News

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

Michael O'Riordan

July 17, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Advertisement

Low Rate of Bailout Emergency Surgery During TAVR, but Caution Still Needed

Sex Differences Diminish With Third-Generation TAVR Device

Sex-Specific Outcomes of TAVR With the SAPIEN 3 Valve

Novel Repositionable TAVR Device Sees Low Pacemaker Rates and Few Leaks

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

CT Scans Before and After TAVR Show Tricuspid, Bicuspid Valves Are Reassuringly Similar

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Association of PVR With 1-Year Outcomes After TAVR With Sapien 3 Valve

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

Standardized Minimalistic Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using the SAPIEN 3 Device: Stepwise Description, Feasibility, and Safety from a Large Consecutive Single-Center Single-Operator Cohort

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content